3
Announcements
Trials
Browse
Landscape
Phase
Phase 3
1
Status
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
NET
1
Gastrointestinal
1
Endocrine
1
Conditions
Breast Neoplasms
74
Colorectal Neoplasms
43
Rectal Neoplasms
42
Stomach Neoplasms
39
Triple Negative Breast Neoplasms
30
Neoplasm Metastasis
19
Esophageal Neoplasms
16
Colonic Neoplasms
16
Neoplasms
13
Pancreatic Neoplasms
12
Parkinson Disease 4, Autosomal Dominant Lewy Body
11
Nasopharyngeal Carcinoma
11
Adenocarcinoma
11
Biliary Tract Neoplasms
10
Adenocarcinoma Of Esophagus
9
Cholangiocarcinoma
7
Locally Advanced Rectal Cancer
6
Esophageal Squamous Cell Carcinoma
6
Brain Neoplasms
6
Anus Neoplasms
6
Recurrence
5
Neuroendocrine Tumors
5
Gastrointestinal Neoplasms
5
Squamous Cell Carcinoma of Head and Neck
4
HER2-positive Breast Cancer
4
Colorectal Cancer Metastatic
4
Carcinoma, Non-Small-Cell Lung
4
Carcinoma, Hepatocellular
4
Advanced Solid Tumors
4
Pathologic Complete Response
3
Interventions
lutetium Lu 177 dotatate
6
Octreotide
3
pasireotide
2
lanreotide
2
gallium Ga 68 dotatate
2
copper dotatate CU-64
2
amino-acid, glucose, and electrolyte solution
2
Magnetic Resonance Spectroscopy
2
Lutetium-177
2
Lutetium
2
Ga(III)-DOTATOC
2
Everolimus
2
177Lu-octreotide, DOTA(0)-Tyr(3)-
2
zimberelimab
1
irinotecan sucrosofate
1
abemaciclib
1
X-Rays
1
Temozolomide
1
Sunitinib
1
Receptor-Like Protein Tyrosine Phosphatases, Class 2
1
Radiosurgery
1
PM 01183
1
Oxaliplatin
1
Nivolumab
1
Leucovorin
1
Irinotecan
1
Ipilimumab
1
Folfox protocol
1
Fluorouracil
1
E-7386
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Gastro-enteropancreatic neuroendocrine tumor
×
Capecitabine
×
1 year
×
Clear all
NCT04919226
2025-09-10
COMPOSE
ITM Solucin GmbH
Phase 3
Active not recruiting
259 enrolled